Abingdon Health PLC - York, England-based lateral flow contract research and contract development & manufacturing organisation - Says subsidiary CS (Lifesciences) Ltd has won a 12-month contract with an unnamed global diagnostics company, due to begin in March. The contract provides revenue of just under £500,000 and will see CS (Lifesciences) carry out work relating to quality management systems and regulatory approvals.

Abingdon acquired CS (Lifesciences), a consultancy specialising in compliance requirements for international IVD and medical device markets, in August 2024.

Abingdon Chief Executive Officer Chris Yates says: ‘This contract win illustrates one aspect of Abingdon’s service offering in the medical diagnostic sector and to the wider med-tech industry. Our full CDMO [contract development & manufacturing] service, offering services to an international customer base, has been enhanced by our recent acquisition of CS (Lifescience) Ltd.’

Current stock price: 8.50 pence, up 6.3% in London on Wednesday afternoon

12-month change: down 17%

Copyright 2025 Alliance News Ltd. All Rights Reserved.